LCM
PYXS icon

Laurion Capital Management’s Pyxis Oncology PYXS Stock Holding History

Laurion Capital Management’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.8M Sell
4,900,888
-96,445
-2% -$184K 0.38% 70
2026
Q1 		$7.3M Buy
4,997,333
+200,854
+4% +$303K 0.32% 91
2025
Q4 		$5.52M Buy
4,796,479
+1,170,505
+32% +$4.13M 0.21% 78
2025
Q3 		$8.05M Hold
3,625,974
– – 0.14% 109
2025
Q2 		$3.99M Hold
3,625,974
– – 0.07% 139
2025
Q1 		$3.55M Hold
3,625,974
– – 0.09% 125
2024
Q4 		$5.66M Hold
3,625,974
– – 0.1% 137
2024
Q3 		$13.3M Sell
3,625,974
-235,205
-6% -$823K 0.18% 60
2024
Q2 		$12.8M Hold
3,861,179
– – 0.15% 99
2024
Q1 		$16.4M Buy
3,861,179
+690,376
+22% +$2.9M 0.14% 140
2023
Q4 		$5.71M Hold
3,170,803
– – 0.05% 233
2023
Q3 		$6.31M Hold
3,170,803
– – 0.04% 262
2023
Q2 		$8.12M Hold
3,170,803
– – 0.05% 228
2023
Q1 		$12.7M Hold
3,170,803
– – 0.09% 183
2022
Q4 		$4.25M Hold
3,170,803
– – 0.02% 273
2022
Q3 		$6.25M Hold
3,170,803
– – 0.04% 234
2022
Q2 		$7.55M Buy
3,170,803
+1,950,971
+160% +$5.19M 0.12% 133
2022
Q1 		$4.93M Buy
1,219,832
+57,500
+5% +$420K 0.06% 166
2021
Q4 		$12.8M Buy
+1,162,332
New +$13.3M 0.13% 109

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Laurion Capital Management's PYXS Position: Q2 2026 in Review

Laurion Capital Management reduced its Pyxis Oncology (PYXS) stake by 1.9% in Q2 2026, selling an estimated $184K and leaving 4,900,888 shares worth $14.8M. The position accounts for 0.38% of the portfolio, ranked #70.

Laurion Capital Management first reported a position in PYXS in Q4 2021 and has held it in 19 quarters since. The position peaked at $16.4M in Q1 2024. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • Laurion Capital Management held 4,900,888 shares of Pyxis Oncology worth $14.8M as of Q2 2026.
  • Laurion Capital Management sold 96,445 Pyxis Oncology shares in Q2 2026, an estimated $184K.
  • Pyxis Oncology made up 0.38% of Laurion Capital Management's portfolio in Q2 2026, its #70 holding.
  • Laurion Capital Management first reported a position in Pyxis Oncology in Q4 2021 and has held it in 19 quarters since.
  • Laurion Capital Management's Pyxis Oncology position peaked at $16.4M in Q1 2024.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Laurion Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.